Twist Bioscience Corp (TWST): Results of Operations and Financial Condition
Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY2026 revenue range ($456-$457M vs prior $442-$447M) and the reiterated expectation to reach adjusted EBITDA breakeven in Q4 FY26, alongside reported gross margin improvement to 52.8%.
Market read
A fresh earnings-and-guidance disclosure with explicit revenue and margin targets, likely prompting near-term estimate revisions and positioning ahead of the Q4 breakeven milestone.
What to watch
SG&A rose to $80.7M from $63.4M year over year, and adjusted EBITDA was still $(11.3)M in 3Q, so margin and cost discipline into Q4 are key to follow-through.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Twist’s fiscal third quarter ended June 30, 2026 results and updated FY2026 guidance.
Ticker impact
Twist reported 3QFY26 revenue of $118.4M, raised FY2026 revenue guidance to $456-$457M, and reiterated Q4 adjusted EBITDA breakeven.
Likely positive bias for the next session and into the next earnings window, with focus on whether DSPS and NGS momentum sustains.
The filing discloses fresh, quantified results and updated full-year revenue guidance, which typically drives revisions to forward estimates and discount-rate expectations for growth biotechs.
Market effects
Reinforces investor appetite for profitable-path genomics and DNA synthesis platforms, potentially supporting sentiment across value biotech with improving gross margins.
Limited, primarily company-specific impact for a South San Francisco biotech.
Modest, as the disclosure is company-specific and not a sector-wide regulatory or macro shock.
Counterpoint
Despite revenue growth, TWST still reported a sizable net loss and adjusted EBITDA remains negative in 3Q, so the market may discount the breakeven claim until achieved.
Key entities
- companyTwist Bioscience Corporation
NASDAQ-listed genomics and DNA synthesis company reporting 3QFY26 results and raising FY2026 revenue guidance.
- executiveEmily M. Leproust, Ph.D.
CEO and co-founder quoted on growth trajectory and adjusted EBITDA breakeven expectation.
